Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Expert opinion on biological therapy - 1 Aug 2009

Heimberger Amy B, Sampson John H

Abstract excerpt

Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, resulting in non-specific toxicity. Immune targeting of tumor-specific mutations may allow for more precise eradication of neoplastic cells. EGFR variant III (EGFRvIII) is a tumor-specific mutation that is widely expressed in GBM and other neoplasms and its expression enhances tumorigenicity. This in-frame deletion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cancer Vaccines
Share to Central Nervous System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to ErbB Receptors

Share to Glioblastoma

Share to Immunotherapy

Share to Peptides

Source

Open in PubMed Open full text

Identifiers

PMID: 19591631
DOI: 10.1517/14712590903124346
PMCID: PMC2793529

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.PMID 19591631Read ↗

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomasSemantic proximity Read ↗

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.Semantic proximity Read ↗

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Semantic proximity Read ↗

Prospect of rindopepimut in the treatment of glioblastomaSemantic proximity Read ↗

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant GliomasSemantic proximity Read ↗

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escapeSemantic proximity Read ↗

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.Semantic proximity Read ↗

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.Semantic proximity Read ↗

A Specific Peptide Vaccine Against IDH1(R132H) Glioma.Semantic proximity Read ↗

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.Semantic proximity Read ↗

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.Semantic proximity Read ↗

Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.